Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Entrada Therapeutics, Inc. (TRDA : NSDQ)

• Company Description    Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON. Number of Employees: 183

• Price / Volume Information    Yesterday's Closing Price: $10.28 Daily Weekly Monthly 20 Day Moving Average: 158,744 shares Shares Outstanding: 38.22 (millions) Market Capitalization: $392.89 (millions) Beta: -0.12 52 Week High: $18.76 52 Week Low: $4.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.18% 1.35% 12 Week 51.40% 48.96% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Design Center Place Suite 17-500 - Boston,MA 02210 USA ph: 857-520-9158 fax: - investors@entradatx.com http://www.entradatx.com

• General Corporate Information    Officers Dipal Doshi - Chief Executive Officer Kush M. Parmar - Chairman Kory Wentworth - Chief Financial Officer Gina Chapman - Director Peter S. Kim - Director Peer Information Entrada Therapeutics, Inc. (CORR.) Entrada Therapeutics, Inc. (RSPI) Entrada Therapeutics, Inc. (CGXP) Entrada Therapeutics, Inc. (BGEN) Entrada Therapeutics, Inc. (GTBP) Entrada Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29384C108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 38.22 Most Recent Split Date: (:1) Beta: -0.12 Market Capitalization: $392.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.15 Price/Cash Flow: 6.48 Price / Sales: 6.39 EPS Growth vs. Year Ago Period: -202.86% vs. Previous Quarter: -1.92% Sales Growth vs. Year Ago Period: -91.75% vs. Previous Quarter: -17.23% ROE 12/31/25 - - 09/30/25 - -26.42 06/30/25 - -17.81 ROA 12/31/25 - - 09/30/25 - -22.08 06/30/25 - -14.55 Current Ratio 12/31/25 - - 09/30/25 - 14.08 06/30/25 - 18.64 Quick Ratio 12/31/25 - - 09/30/25 - 14.08 06/30/25 - 18.64 Operating Margin 12/31/25 - - 09/30/25 - -168.16 06/30/25 - -92.30 Net Margin 12/31/25 - - 09/30/25 - -168.16 06/30/25 - -92.30 Pre-Tax Margin 12/31/25 - - 09/30/25 - -169.85 06/30/25 - -96.76 Book Value 12/31/25 - - 09/30/25 - 8.96 06/30/25 - 10.00 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©